GAITHERSBURG, Md., April 9 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI - News) announced today that it anticipates its first-quarter diluted earnings per share (EPS), excluding share-based compensation expense, to be in the range of $0.62 to $0.67, as compared to $0.23 in diluted EPS in the 2006 first quarter, excluding share-based compensation. This nearly three-fold increase in expected EPS is due to an estimated 11-to-12 percent increase in total revenues and a greater than two-fold increase in net income margin. The company also stated that for the 2007 first quarter, it expects domestic and worldwide net sales growth of approximately 9-to-10 percent for Synagis® (palivizumab) over the same quarter in 2006.
